Navigation Links
WuXi AppTec VP and GM Invited to Join the AAMI Standards Board

SHANGHAI, China, July 9 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that Ms. Trabue D. Bryans, Vice President and General Manager of WuXi AppTec's Atlanta Operations, one of the U.S. operating subsidiaries of WuXi PharmaTech (Cayman) Inc., has been invited to join the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board for a three-year term.

(Logo: )

Founded in 1967, the non-profit AAMI is a unique alliance of over 6,000 individuals and 375 organizations from around the world united by the common goal of increasing the understanding and beneficial use of medical instrumentation, as well as the primary resource for the industry, professions, and government for national and international standards. The AAMI standards program consists of over 100 technical committees and working groups that produce Standards, Recommended Practices, and Technical Information Reports for medical devices. Standards and Recommended Practices represent a national consensus and many have been approved by the American National Standards Institute (ANSI) as American National Standards as well as International Standardization Organization (ISO) standards.

Having served as a member of AAMI Sterilization Standards Committee, former co-chair of the AAMI Microbiological Methods Working Group, and expert member to the ISO TC 198 Micro Methods working group, Ms. Bryans will work regularly with more important responsibilities in her new role of directing and supervising all AAMI technical committee activities relating to the national standards program.

''I am very honored to be part of the national standards program, and will do my best to make a worthwhile contribution during my term. As the global medical device industry is rapidly growing and related technologies and products are converging, it is very important to have a set of standards that help regulate the research, development and commercialization of innovative medical devices,'' said Ms. Bryans.

With over 25 years of experience in medical device industry and internationally recognized for her work in microbiology and sterilization and process validation, Ms. Bryans is responsible for all operations of WuXi AppTec's Atlanta facility. She received her B.S. from University of Georgia, and M(ASCP), microbiology technologist certification by the American Society for Clinical Pathology, from Medical College of Georgia. She also completed her M.B.A. course work at Georgia State University.

''We are very proud of Trabue for her expertise and professional status,'' commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. ''We are delighted to have such an exceptional individual whose leadership has made tremendous impact on not only national standards but also the medical device testing business of WuXi AppTec. We would like to extend our warm congratulations to Trabue and great support for her new role in AAMI.''

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: .

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Completes Acquisition of AppTec
2. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
3. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
4. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
5. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
6. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
7. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
8. Allergy Standards LTD to Attend 2008 American Academy of Allergy, Asthma and Immunology Conference
9. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
10. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
11. CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public
Post Your Comments:
(Date:11/24/2015)... Switzerland (PRWEB) , ... November 24, 2015 , ... ... plant and the environment are paramount. Insertion points for in-line sensors can represent ... has developed the InTrac 781/784 series of retractable sensor housings , which ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/23/2015)... , Nov. 24, 2015 Women with a ... CT exams face a higher risk of lung cancer than ... presented next week at the annual meeting of the Radiological ... --> --> Lung nodules ... classified as solid or subsolid based on their appearance on ...
(Date:11/23/2015)... The royalty-free a greement a llows ... 112 low- and m iddle-i ncome ... --> The Medicines Patent Pool (MPP) today announced its ... with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral that ... virus.  The royalty-free licence will enable generic manufacture of daclatasvir ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
Breaking Biology News(10 mins):